Hospital Acquired Infection Treatment Market Trends, 2019-2027

Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Hospital Acquired Infection Treatment Market Rides on Increased Prevalence of HAI Worldwide

A hospital-acquired infection (HAI) is also otherwise known as a nosocomial infection. It is a type of infection that is contacted in a healthcare facility or in a hospital. The infection is also known as health care–associated infection in an effort to emphasize on both non-hospital and hospital settings. A rise in the incidences of such an infection is expected to give a boost to the global hospital acquired infection treatment market over the timeframe of projection.

Fungal, bacterial, and viral pathogens cause hospital-acquired infections. The most common types are surgical site infection (SSI), urinary tract infection (UTI), pneumonia (such as ventilator-associated pneumonia), and bloodstream infection (BSI).

Market Growth to be driven by Vulnerability of Newborn Babies toward HAI

In some cases, hospital acquired infection manifests itself weeks after discharge from the hospital though it had been contacted in the hospital. The infection could also infect the hospital staff and caregivers associated with taking care of such patients. Such high prevalence and contagiousness of the infection is likely to spell growth for the global hospital acquired infection treatment market in near future.

Many antimicrobial drugs have proven to be highly effective in treating a wide range of hospital-related infections that are highly prevalent across the globe. Treatments of hospital-acquired infections comprise the following

  • Antifungal therapy
  • Antiviral therapy

The most sterilized sections of the hospital are the neonatal intensive care units (NICUs), which keeps infants as they are more vulnerable to such infections during the span of their hospital stay.  The National Institute of Child Health and Human Development (NICHD) conducted a study titled “Neonatal Network”. The study projected that around 29% of the infants born at 25 to 28 weeks of gestation period and 46% of the newborns born at less than 25 weeks of gestation are estimated to experience severe hospital acquired infection over the period of hospitalization at NICU. High vulnerability of infants likely to play an important role in the development of the global hospital acquired infection treatment market in near future. 

  • According to Transparency Market Research’s latest report on the global hospital acquired infection treatment (HAI) market for the historical period 2017–2018 and forecast period 2019–2027, unhygienic conditions and improper sterilization treatment, lack of surveillance systems for HAIs, high susceptibility of neonatal population, and rising geriatric population are projected to drive the global hospital acquired infection treatment (HAI) market during the forecast period
  • According to the report, the global hospital acquired infection treatment (HAI) market was valued at US$ 31.0 Bn in 2018 and is anticipated to expand at a CAGR of 2.5% from 2019 to 2027
fa global hospital acquired infection treatment market

Rising Geriatric Population and Unhygienic Conditions and Improper Sterilization Treatment: Key Drivers

  • Continuous increase in the geriatric population is expected to be one of the potential drivers of the hospital acquired infection (HAI) treatment market during the forecast period. The geriatric population is at high risk of infection due to the age-related immunity decline, known as immunosenescence. Moreover, such patients required more time to heal and hospital stay to get recovered.
  • Increase in need for effective antibacterial treatment options for the geriatric population is expected to drive the demand for the hospital acquired infection treatment (HAI) market
    • According to WHO estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, which is currently 566 million.
  • Hospital acquired infections are one the highly frequent adverse events in the health care industry. Presence of unhygienic conditions around and inside the hospital along with improper sterilization techniques applied in the hospitals are increasing the prevalence of hospital acquired infection in low income and middle income countries.
  • According to an article published by Global Antibiotic Resistance Partnership (GARP), more than 190,000 neonatal deaths occurred in India annually due to infection

Lack of Surveillance Systems for HAIs Boost Market Growth

  • Increasing prevalence of HAIs is because most countries do not have surveillance systems for HAIs, while the countries that have the systems in place often face difficulties with the complexity and lack of standardized criteria for diagnosing the infections. Countries in North America and Europe have surveillance systems for HAI monitoring while countries in Asia Pacific and rest of the world do not have the systems, which makes it difficult to control the outbreak of endemics in these regions.
  • The Healthcare-Associated Infections Surveillance Network (HAI-Net), National Healthcare Safety Network (NHSN), and Japan Nosocomial Infection Surveillance System (JANIS) are some of the surveillance systems working efficiently in developed countries

Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated to Hamper Market

  • Multi-drug resistance is one of the most common causes of failure in treatment for bacterial infection. Bacteria are the only species that can survive even after frequent exposure to one or more antibiotics and develop drug resistance.
  • Moreover, these infections result in higher rate of disability and death compared to the infections that are easily treatable with antibiotics. Multi-drug resistance is affecting the HAI treatment market due to the shift of treatment process.
  • Major types of multi-drug resistant bacteria are methicillin resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB).

 Global Hospital Acquired Infection Treatment (HAI) Market: Competitive Landscape

  • This report profiles major players in the global hospital acquired infection treatment (HAI) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global hospital acquired infection treatment (HAI) market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global hospital acquired infection treatment (HAI) market
    • Abbott Laboratories
    • Pfizer, Inc.
    • Bayer AG
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Cipla Inc.
    • GlaxoSmithKline plc
    • Aridis Pharmaceuticals, Inc
    • Astellas Pharma Inc.
    • Daiichi Sankyo, Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company among others.

Global Hospital Acquired Infection Treatment (HAI) Market: Key Developments

Key players in the global hospital acquired infection treatment (HAI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global hospital acquired infection treatment (HAI) market. A few expansion strategies adopted by players operating in the global hospital acquired infection treatment (HAI) market are:

  • In July 2019, Pfizer Inc. completed acquisition of the privately-held clinical-stage biotechnology company Therachon Holding AG for US$ 340 Mn. Therachon represented the Rare Disease team of Pfizer to develop innovative medicines to treat rare diseases.
  • In December 2018, Pfizer Inc. and GlaxoSmithKline plc entered into an agreement to create a premier global consumer health care company with iconic brands. In 2017, the combined business was approximately US$ 12.7 Bn.

 The report on the global hospital acquired infection treatment (HAI) market discussed individual strategies, followed by company profiles of manufacturers of hospital acquired infection treatment (HAI). The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hospital acquired infection treatment (HAI) market.

Global Hospital acquired infection treatment (HAI) Market - Segmentation

Infection Type

  • Urinary Tract Infection
  • Ventilator-Associated Pneumonia
  • Bloodstream Infection
  • Surgical Site Infection
  • Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

Treatment

Antibacterial Treatment

  • Beta-Lactams
  • Quinolones
  • Vancomycin
  • Other

Antiviral Treatment

  • Acyclovir
  • Foscarnet

Antifungal Treatment

  • Amphotericin B
  • Triazoles

Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • E-Commerce
  • Other

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of hospital acquired infection treatment market?

Hospital acquired infection treatment market to reach US$ 38.8 Bn by 2027

What is the anticipated CAGR of the hospital acquired infection treatment market in the forecast period?

Hospital acquired infection treatment market is anticipated to expand at a CAGR of 2.5% from 2019 to 2027

What are the key driving factors for the growth of the hospital acquired infection treatment market?

Hospital acquired infection treatment market is driven by increase in need for effective antibacterial treatment options for the geriatric population

Which region is expected to project the highest market share in the global hospital acquired infection treatment market?

North America accounted for major share of the global hospital acquired infection treatment (HAI) market, owing to high cost associated with hospital acquired infection treatments

Who are the key players in the global hospital acquired infection treatment market?

Key players in the global hospital acquired infection treatment market include Abbott Laboratories, Pfizer, Inc., Bayer AG, AstraZeneca, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Cipla Inc.

     1.  Preface

         1.1.  Market Definition and Scope

         1.2.  Market Segmentation

         1.3.  Key Research Objectives

         1.4.  Research Highlights

     2.  Assumptions and Research Methodology

     3.  Executive Summary : Global Hospital Acquired Infection Treatment (HAI) Market

     4.  Market Overview

         4.1.  Introduction

         4.2.  Overview

         4.3.  Market Dynamics

             4.3.1. Drivers

             4.3.2. Restraints

             4.3.3. Opportunities

         4.4. Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, 2017–2027

         4.5. Porter’s Five Force Analysis

     5.  Key Insights

         5.1. Guidelines for Hospital Acquired Infection Treatment

         5.2. Epidemiology of Hospital Acquired Infection, By Key Countries

         5.3. Regulations for Controlling Hospital Acquired Infection, By Region

         5.4. Future Market Outlook

     6.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Infection Type 

         6.1. Introduction & Definition

         6.2. Key Findings / Developments

         6.3. Market Value  Forecast By Infection Type, 2017–2027

             6.3.1. Urinary Tract Infection 

             6.3.2. Ventilator-Associated Pneumonia 

             6.3.3. Bloodstream Infection  

             6.3.4. Surgical Site Infection

             6.3.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         6.4. Market Attractiveness By Infection Type 

     7.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Treatment 

         7.1. Introduction & Definition

         7.2. Key Findings / Developments

         7.3. Market Value  Forecast By Treatment, 2017–2027

             7.3.1. Antibacterial Treatment

                 7.3.1.1. Beta-Lactams

                 7.3.1.2. Quinolones

                 7.3.1.3. Vancomycin

                 7.3.1.4. Other

             7.3.2. Antiviral Treatment 

                 7.3.2.1. Acyclovir 

                 7.3.2.2. Foscarnet 

             7.3.3. Antifungal Treatment 

                 7.3.3.1. Amphotericin B 

                 7.3.3.2. Triazoles

             7.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         7.4. Market Attractiveness By Treatment 

     8.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Distribution Channel 

         8.1. Introduction & Definition

         8.2. Key Findings / Developments

         8.3. Market Value  Forecast By Distribution Channel, 2017–2027

             8.3.1. Hospital Pharmacies 

             8.3.2. Retail Pharmacies

             8.3.3. Drug Store 

             8.3.4. E-Commerce 

             8.3.5. Other

         8.4. Market Attractiveness By Distribution Channel 

     9.  Global Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecasts, By Region

         9.1. Key Findings

         9.2. Market Value  Forecast By Region

             9.2.1. North America 

             9.2.2. Europe 

             9.2.3. Asia Pacific 

             9.2.4. Latin America 

             9.2.5. Middle East & Africa 

         9.3. Market Attractiveness By Region

     10. North America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

         10.1. Introduction

         10.2. Market Value  Forecast By Infection Type, 2017–2027

             10.2.1. Urinary Tract Infection 

             10.2.2. Ventilator-Associated Pneumonia 

             10.2.3. Bloodstream Infection  

             10.2.4. Surgical Site Infection

             10.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         10.3. Market Value  Forecast By Treatment, 2017–2027

             10.3.1. Antibacterial Treatment

                 10.3.1.1. Beta-Lactams

                 10.3.1.2. Quinolones

                 10.3.1.3. Vancomycin

                 10.3.1.4. Other

             10.3.2. Antiviral Treatment 

                 10.3.2.1. Acyclovir 

                 10.3.2.2. Foscarnet 

             10.3.3. Antifungal Treatment 

                 10.3.3.1. Amphotericin B 

                 10.3.3.2. Triazoles

             10.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         10.4. Market Value  Forecast By Distribution Channel, 2017–2027

             10.4.1. Hospital Pharmacies 

             10.4.2. Retail Pharmacies

             10.4.3. Drug Store 

             10.4.4. E-Commerce 

             10.4.5. Other

         10.5. Market Value  Forecast By Country, 2017–2027

             10.5.1. U.S.

             10.5.2. Canada

         10.6. Market Attractiveness Analysis 

             10.6.1. By Infection Type 

             10.6.2. By Treatment 

             10.6.3. By Distribution Channel 

             10.6.4. By Country

     11. Europe Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

         11.1. Introduction

         11.2. Market Value  Forecast By Infection Type, 2017–2027

             11.2.1. Urinary Tract Infection 

             11.2.2. Ventilator-Associated Pneumonia 

             11.2.3. Bloodstream Infection  

             11.2.4. Surgical Site Infection

             11.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         11.3. Market Value  Forecast By Treatment, 2017–2027

             11.3.1. Antibacterial Treatment

                 11.3.1.1. Beta-Lactams

                 11.3.1.2. Quinolones

                 11.3.1.3. Vancomycin

                 11.3.1.4. Other

             11.3.2. Antiviral Treatment 

                 11.3.2.1. Acyclovir 

                 11.3.2.2. Foscarnet 

             11.3.3. Antifungal Treatment 

                 11.3.3.1. Amphotericin B 

                 11.3.3.2. Triazoles

             11.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         11.4. Market Value  Forecast By Distribution Channel, 2017–2027

             11.4.1. Hospital Pharmacies 

             11.4.2. Retail Pharmacies

             11.4.3. Drug Store 

             11.4.4. E-Commerce 

             11.4.5. Other

         11.5. Market Value  Forecast By Country, 2017–2027

             11.5.1. Germany

             11.5.2. U.K.

             11.5.3. France

             11.5.4. Spain

             11.5.5. Italy

             11.5.6. Rest of Europe

         11.6. Market Attractiveness Analysis 

             11.6.1. By Infection Type 

             11.6.2. By Treatment 

             11.6.3. By Distribution Channel 

             11.6.4. By Country

     12. Asia Pacific Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

         12.1. Introduction

         12.2. Market Value  Forecast By Infection Type, 2017–2027

             12.2.1. Urinary Tract Infection 

             12.2.2. Ventilator-Associated Pneumonia 

             12.2.3. Bloodstream Infection  

             12.2.4. Surgical Site Infection

             12.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         12.3. Market Value  Forecast By Treatment, 2017–2027

             12.3.1. Antibacterial Treatment

                 12.3.1.1. Beta-Lactams

                 12.3.1.2. Quinolones

                 12.3.1.3. Vancomycin

                 12.3.1.4. Other

             12.3.2. Antiviral Treatment 

                 12.3.2.1. Acyclovir 

                 12.3.2.2. Foscarnet 

             12.3.3. Antifungal Treatment 

                 12.3.3.1. Amphotericin B 

                 12.3.3.2. Triazoles

             12.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         12.4. Market Value  Forecast By Distribution Channel, 2017–2027

             12.4.1. Hospital Pharmacies 

             12.4.2. Retail Pharmacies

             12.4.3. Drug Store 

             12.4.4. E-Commerce 

             12.4.5. Other

         12.5. Market Value  Forecast By Country, 2017–2027

             12.5.1. China

             12.5.2. Japan

             12.5.3. India

             12.5.4. Australia & New Zealand

             12.5.5. Rest of Asia Pacific

         12.6. Market Attractiveness Analysis 

             12.6.1. By Infection Type 

             12.6.2. By Treatment 

             12.6.3. By Distribution Channel 

             12.6.4. By Country

     13. Latin America Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

         13.1. Introduction

         13.2. Market Value  Forecast By Infection Type, 2017–2027

             13.2.1. Urinary Tract Infection 

             13.2.2. Ventilator-Associated Pneumonia 

             13.2.3. Bloodstream Infection  

             13.2.4. Surgical Site Infection

             13.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         13.3. Market Value  Forecast By Treatment, 2017–2027

             13.3.1. Antibacterial Treatment

                 13.3.1.1. Beta-Lactams

                 13.3.1.2. Quinolones

                 13.3.1.3. Vancomycin

                 13.3.1.4. Other

             13.3.2. Antiviral Treatment 

                 13.3.2.1. Acyclovir 

                 13.3.2.2. Foscarnet 

             13.3.3. Antifungal Treatment 

                 13.3.3.1. Amphotericin B 

                 13.3.3.2. Triazoles

             13.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         13.4. Market Value  Forecast By Distribution Channel, 2017–2027

             13.4.1. Hospital Pharmacies 

             13.4.2. Retail Pharmacies

             13.4.3. Drug Store 

             13.4.4. E-Commerce 

             13.4.5. Other

         13.5. Market Value  Forecast By Country, 2017–2027

             13.5.1. Brazil

             13.5.2. Mexico

             13.5.3. Rest of Latin America

         13.6. Market Attractiveness Analysis 

             13.6.1. By Infection Type 

             13.6.2. By Treatment 

             13.6.3. By Distribution Channel 

             13.6.4. By Country

     14. Middle East & Africa Hospital Acquired Infection Treatment (HAI) Market Analysis and Forecast

         14.1. Introduction

         14.2. Market Value  Forecast By Infection Type, 2017–2027

             14.2.1. Urinary Tract Infection 

             14.2.2. Ventilator-Associated Pneumonia 

             14.2.3. Bloodstream Infection  

             14.2.4. Surgical Site Infection

             14.2.5. Other (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

         14.3. Market Value  Forecast By Treatment, 2017–2027

             14.3.1. Antibacterial Treatment

                 14.3.1.1. Beta-Lactams

                 14.3.1.2. Quinolones

                 14.3.1.3. Vancomycin

                 14.3.1.4. Other

             14.3.2. Antiviral Treatment 

                 14.3.2.1. Acyclovir 

                 14.3.2.2. Foscarnet 

             14.3.3. Antifungal Treatment 

                 14.3.3.1. Amphotericin B 

                 14.3.3.2. Triazoles

             14.3.4. Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

         14.4. Market Value  Forecast By Distribution Channel, 2017–2027

             14.4.1. Hospital Pharmacies 

             14.4.2. Retail Pharmacies

             14.4.3. Drug Store 

             14.4.4. E-Commerce 

             14.4.5. Other

         14.5. Market Value  Forecast By Country, 2017–2027

             14.5.1. GCC Countries

             14.5.2. South Africa

             14.5.3. Rest of Middle East & Africa

         14.6. Market Attractiveness Analysis 

             14.6.1. By Infection Type 

             14.6.2. By Treatment 

             14.6.3. By Distribution Channel 

             14.6.4. By Country

     15. Competition Landscape

         15.1. Market Player – Competition Matrix (By Tier and Size of companies)

         15.2. Market Share Analysis By Company (2018)

         15.3. Company Profiles

             15.3.1. Abbott Laboratories

                 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.1.2. Company Financials

                 15.3.1.3. Growth Strategies

                 15.3.1.4. SWOT Analysis

             15.3.2. Pfizer Inc. 

                 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.2.2. Company Financials

                 15.3.2.3. Growth Strategies

                 15.3.2.4. SWOT Analysis

             15.3.3. Bayer AG

                 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.3.2. Company Financials

                 15.3.3.3. Growth Strategies

                 15.3.3.4. SWOT Analysis

             15.3.4. Cepheid, Inc.

                 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.4.2. Company Financials

                 15.3.4.3. Growth Strategies

                 15.3.4.4. SWOT Analysis

             15.3.5. AstraZeneca plc

                 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.5.2. Company Financials

                 15.3.5.3. Growth Strategies

                 15.3.5.4. SWOT Analysis

             15.3.6. F. Hoffmann-La Roche Ltd

                 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.6.2. Company Financials

                 15.3.6.3. Growth Strategies

                 15.3.6.4. SWOT Analysis

             15.3.7. Johnson & Johnson Services, Inc.

                 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.7.2. Company Financials

                 15.3.7.3. Growth Strategies

                 15.3.7.4. SWOT Analysis

             15.3.8. Merck & Co., Inc. 

                 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.8.2. Company Financials

                 15.3.8.3. Growth Strategies

                 15.3.8.4. SWOT Analysis

             15.3.9. Cipla Inc.

                 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.9.2. Company Financials

                 15.3.9.3. Growth Strategies

                 15.3.9.4. SWOT Analysis

             15.3.10. GlaxoSmithKline plc. 

                 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.10.2. Company Financials

                 15.3.10.3. Growth Strategies

                 15.3.10.4. SWOT Analysis

             15.3.11. Aridis Pharmaceuticals, Inc.

                 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.11.2. Company Financials

                 15.3.11.3. Growth Strategies

                 15.3.11.4. SWOT Analysis

             15.3.12. Astellas Pharma Inc.

                 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.12.2. Company Financials

                 15.3.12.3. Growth Strategies

                 15.3.12.4. SWOT Analysis

             15.3.13. Daiichi Sankyo, Inc.

                 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.13.2. Company Financials

                 15.3.13.3. Growth Strategies

                 15.3.13.4. SWOT Analysis

             15.3.14. Bristol-Myers Squibb Company

                 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.14.2. Company Financials

                 15.3.14.3. Growth Strategies

                 15.3.14.4. SWOT Analysis

             15.3.15. Eli Lilly and Company

                 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

                 15.3.15.2. Company Financials

                 15.3.15.3. Growth Strategies

                 15.3.15.4. SWOT Analysis

    List of Tables

    Table 01: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 02: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 03: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 04: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 05: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2019–2027

    Table 06: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 07: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 08: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 09: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 10: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 11: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Other Treatments, 2019–2027

    Table 12: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 13: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 14: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 15: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 16: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 17: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2019–2027

    Table 18: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 19: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 20: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 21: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 22: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 23: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2019–2027

    Table 24: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 25: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 26: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 27:  Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 28:  Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 29:  Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2019–2027

    Table 30: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel,

    Table 31: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2019–2027

    Table 32: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2019–2027

    Table 33: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2019–2027

    Table 34: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2019–2027

    Table 35: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2019–2027

    Table 36: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    List of Figure

    Figure 01: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027

    Figure 02: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Urinary Tract Infection

    Figure 03: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Ventilator-associated Pneumonia (VAP)

    Figure 04: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Bloodstream Infection

    Figure 05: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Surgical Site Infection

    Figure 06: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Other Infections

    Figure 07: Global Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 08: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Infection Type, 2016 and 2024

    Figure 09: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antibacterial Treatment

    Figure 10: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antiviral Treatment

    Figure 11: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antifungal Treatment

    Figure 12: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Other Treatments

    Figure 13: Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 14: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Treatment, 2016 and 2024

    Figure 15: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Hospital Pharmacies

    Figure 16: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Retail Pharmacies 

    Figure 17: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Drug Stores

    Figure 18: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by E-commerce

    Figure 19: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Other Distribution Channels

    Figure 20: Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 21:Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2016 and 2024

    Figure 22: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 23: North America Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2019–2027

    Figure 24: U.S. Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 25: Canada Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 26: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Urinary Tract Infection

    Figure 27: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Ventilator-Associated Pneumonia (VAP)

    Figure 28: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Bloodstream Infection

    Figure 29: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Surgical Site Infection

    Figure 30: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 31: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antibacterial Treatment

    Figure 32: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antiviral Treatment

    Figure 33: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antifungal Treatment

    Figure 34: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 35: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Hospital Pharmacies

    Figure 36: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Retail Pharmacies

    Figure 37: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Drug Stores

    Figure 38: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by E-commerce

    Figure 39: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 40: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 41: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 42: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 43: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 44: Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 45: Europe Hospital acquired Infection Treatment Market Size, Y-o-Y Growth Projections, 2019–2027

    Figure 46: Germany Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 47: The U.K. Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 48: France Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 49: Spain Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 50: Italy Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 51: Rest of Europe Hospital acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 52: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Urinary Tract Infection, 2019–2027

    Figure 53: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Ventilator-associated Pneumonia (VAP), 2019–2027

    Figure 54: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Bloodstream Infection, 2019–2027

    Figure 55: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Surgical Site Infection, 2019–2027

    Figure 56: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Others, 2019–2027

    Figure 57: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2027, by Antibacterial Treatment

    Figure 58: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2027, by Antiviral Treatment

    Figure 59: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2027, by Antifungal Treatment

    Figure 60: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2019–2027, by Others

    Figure 61: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2019–2027

    Figure 62: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2019–2027

    Figure 63: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Drug Stores, 2019–2027

    Figure 64: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by E-commerce, 2019–2027

    Figure 65: Europe Hospital acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Others, 2019–2027

    Figure 66: Europe Hospital acquired Infection Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 67: Europe Hospital acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 68: Europe Hospital acquired Infection Treatment Market Attractiveness Analysis, by Treatment Type, 2019–2027

    Figure 69: Europe Hospital acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 70: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 71: Asia Pacific Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2019–2027

    Figure 72: Japan Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 73: China Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 74: India Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 75: Australia Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 76: Rest of APAC Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 77: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Urinary Tract Infection

    Figure 78: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Ventilator-associated Pneumonia (VAP)

    Figure 79: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Bloodstream Infection

    Figure 80: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Surgical Site Infection

    Figure 81: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 82: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antibacterial Treatment

    Figure 83: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antiviral Treatment

    Figure 84: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antifungal Treatment

    Figure 85: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 86: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Hospital Pharmacies

    Figure 87: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Retail Pharmacies

    Figure 88: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Drug Stores

    Figure 89: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by E-commerce

    Figure 90: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 91: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 92: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 93: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 94: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 95: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 96: Latin America Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2019–2027

    Figure 97: Brazil Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 98: Mexico Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 99: Rest of Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 100: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Urinary Tract Infection

    Figure 101: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Ventilator-Associated Pneumonia (VAP)

    Figure 102: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Bloodstream Infection

    Figure 103:  Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Surgical Site Infection

    Figure 104: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 105: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antibacterial Treatment

    Figure 106: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antiviral Treatment

    Figure 107: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antifungal Treatment

    Figure 108: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 109: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Hospital Pharmacies

    Figure 110:  Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Retail Pharmacies

    Figure 111: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Drug Stores

    Figure 112:  Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by E-Commerce

    Figure 113: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 114: Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 115:  Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 116:  Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 117:  Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 118: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 119: Middle East & Africa Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2019–2027

    Figure 120: South Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 121: UAE Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 122: Rest of Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2019–2027

    Figure 123: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Urinary Tract Infection

    Figure 124: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Ventilator-associated Pneumonia (VAP)

    Figure 125: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Bloodstream Infection

    Figure 126: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Surgical Site Infection

    Figure 127: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 128: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antibacterial Treatment

    Figure 129: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antiviral Treatment

    Figure 130: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Antifungal Treatment

    Figure 131: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 132: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Hospital Pharmacies

    Figure 133: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Retail Pharmacies

    Figure 134: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Drug Stores

    Figure 135: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by E-commerce

    Figure 136: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2019–2027, by Others

    Figure 137: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2019–2027

    Figure 138: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2019–2027

    Figure 139: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2019–2027

    Figure 140: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Copyright © Transparency Market Research, Inc. All Rights reserved